231 results about "Clinical therapy" patented technology

This disclosure provides a newly developed strategy and particular options for differentiating pluripotent stem cells into cells of the hepatocyte lineage. Many of the protocols are based on a strategy in which the cells are first differentiated into early germ layer cells, then into hepatocyte precursors, and then into mature cells. The cells obtained have morphological features and phenotypic markers characteristic of human adult hepatocytes. They also show evidence of cytochrome p450 enzyme activity, validating their utility for commercial applications such as drug screening, or use in the manufacture of medicaments and medical devices for clinical therapy.

The present invention provides for a method to increase the triplet yield of a photosensitizer by the coupling to metal surface plasmons which leads to increased singlet oxygen generation by electric field enhancement or enhanced energy absorption of the photosensitizer. The extent of singlet oxygen enhancement can be tuned for applications in singlet oxygen based clinical therapy by modifying plasmon coupling parameters, such as metallic nanoparticle size and shape, photosensitizer/metallic nanoparticle distance, and the excitation wavelength of the coupling photosensitizer.

The invention relates to uses of Bombay canary and its alcohol extract in preparing medicine for treatment of inflammation, specifically, for treating cervical erosion, ulcerative colitis, fig wart after operation, said invention belongs to medicine field.

This invention describes a novel format of monomeric bispecific fusion protein with immune activating property for clinical therapies. A bispecific fusion protein includes a first targeting domain with a specificity for a first target of interest; a bridging domain derived from a constant region of a light chain or heavy chain of an immunoglobulin, which may be a human immunoglobulin; and a second targeting domain with a specificity for a second target of interest. The bispecific fusion protein may further include a linker fused to the N-terminus or the C-terminus of the bridging domain. The first targeting domain is fused to the bridging domain and the second targeting domain is fused to the bridging domain or the linker. The linker may include a GGGGS sequence. The first target of interest may be CD20, Her2/neu, or EpCAM, and the second targeting domain is a T-lymphocyte activating domain.

Provided are novel nanostructures comprising hollow nanospheres (HGNs) and nanotubes for use as chemical sensors, molecular specific photothermal coupling agents, and photothermal ablation compounds. The nanostructures can be used in electromagnetic radiation-induced phototherapy for treatment of cancer and other disorders. The nanostructures can also be used as a sensor that detects molecules. The nanostructures are of particular use in the fields of clinical diagnosis, clinical therapy, clinical treatment, and clinical evaluation of various diseases and disorders, manufacture of compositions for use in the treatment of various diseases and disorders, for use in molecular biology, structural biology, cell biology, molecular switches, molecular circuits, and molecular computational devices, and the manufacture thereof. The hollow gold nanospheres have a unique combination of spherical shape, small size, and strong, tunable, and narrow surface plasmon resonance absorption covering the entire visible to near IR region.

The present invention discloses the application of bakuchiol compound in preparing medicine for treating psychogenic diseases and neurogenic diseases. Extracorporeal experiment and animal experiment show that the bakuchiol compound can suppressing dopamine transport protein, noradrenalin transport protein and 5-hydroxy tryptamine transport protein selectively, and no influence on gamma-aminobutyric acid transport protein and L-glytamic acid transport protein, no cytotoxicity, and antidepressant effect higher than available antidepressant medicine amfebutamoe hydrochloride. Therefore, the bakuchiol compound has excellent marketability in preparing medicine for treating psychogenic diseases and neurogenic diseases.

The present invention belongs to the field of medicine technology. The compound coenzyme medicine contains CoA, NAD, GSH and ATP; and features that it contains also FMN, FAD, ADP, AMP and SAM. The present invention has improved compound coenzyme medicine preparing process. The compound coenzyme medicine can protect liver cell, myocardial cell and other cells, maintain or restore their normal metabolism, and may be used in heart and liver surgical operation, restoring of damaged liver, restoring damaged cell caused by radiotherapy and chemotherapy.

The invention relates to an accelerator which combines a cyclotron and a synchrotron and is used for cancer therapy with protons-heavy ion beams, comprising an ion source E and the synchrotron C. The accelerator is characterized in that the synchrotron C comprises a septum magnet implanting device (5), a septum magnet extracting device (6), a radio-frequency accelerating device (9), eight bending sections of the synchrotron (1-1 to 1-8) and eight straight sections of the synchrotron (2-1 to 2-8), which are connected by an ion beam transmission line F; the ion beam implantation end of the synchrotron C is provided with a sector focusing cyclotron A or/and a separated sector focusing cyclotron B. By adopting the method of combining the cyclotron and the synchrotron, a set of accelerator devices required by cancer therapy with protons and heavy ion beams is set up to realize the requirements of clinical therapy on beam parameters; the mass numbers of the protons and the heavy ions are less than or equal to 40; the protons and heavy ion beams have wide energy range from 10MeV/u to 400MeV/u and high flux (the ion number provided by each pulse is up to 10<7-10> magnitude).

The invention relates to preparation and storage of umbilical cord-mesenchymal stem cells (UC-MSCs) used in clinical therapy. The preparation method of the UC-MSCs comprises the following steps: cleaning an umbilical cord and cutting the umbilical cord into granules; putting the granules in physiological saline containing 2 percent gentamicin; carrying out centrifugation, suspension and centrifugation; carrying out cultivation for 10 days; carrying out passage in the proportion of 1:3 to between fourth and fifth generation, and obtaining a great amount of mesenchymal stem cells; and finally, putting the mesenchymal stem cells in liquid nitrogen for storage after adding freezing medium and keeping the freezing temperature of the liquid nitrogen at 196 DEG C below zero.

The invention discloses a tumor-targeted delivery carrier based on cell-derived micro-vacuoles, a preparation method and an application. The preparation method comprises the following steps of: (A) preparing a conditioned medium: supplementing fetal bovine serum, antibiotics, DSPE-PEG-Biotin and DSPE-PEG-Folate into a basal medium; (B) using the obtained conditioned medium in cell culture, and collecting cell culture supernatant for subsequent separation; (C) carrying out low-speed centrifugation on the obtained culture supernatant to remove cell debris and apoptotic bodies, then adding SA-IONPs, mixing uniformly, incubating, then separating by a magnet, using PBS for re-suspension, eluting for multiple times to obtain the cell-derived micro-vacuoles with membrane surfaces modified by folic acid and iron oxide nano-particles, and freezing for storage; and (D) loading chemotherapeutic drugs or therapeutic genes into the functionalized micro-vacuoles doubly-modified by an electroporation mode, and carrying out re-suspension after separation with the magnet. The tumor-targeted delivery carrier based on cell-derived micro-vacuoles, the preparation method and the application disclosed by the invention are applicable to specific targeting delivery of multiple chemotherapeutic drugs and therapeutic genes, and have the advantages of enhancing the anti-tumor effect, reducing the systemic toxicity and improving the clinical effect of the current therapeutic selection, so that a new hope is brought for clinical therapy of tumors.

The invention provides a human skin epidermal cell culture medium and application thereof. The culture medium is prepared by the following steps: mixing a K-SFM (keratinocyte serum-free medium), a DMEM (dulbecco's modified eagle medium) and a F12 culture medium according to the ratio of 2:1:1, and adding a BPE (bovine pituitary extract), an EGF (epidermal growth factor), an SCGF (stem cell growth factor), an FGF (fibroblast growth factor), a TGF-beta (transforming growth factor-beta), a VEGF (vascular endothelial growth factor), CaCl2, glutamine and a double-antibody. The culture medium is free of serum, and can be used for human skin epidermal cell primary culture and subculture. The human skin epidermal cell culture medium can obtain abundant epidermal cells by in-vitro culture by using only a small amount of patient skin tissues. Compared with the traditional epidermal cell culture medium, the human skin epidermal cell culture medium provided by the invention greatly shortens the time required by amplifying the same cell count, and satisfies the demands for clinical therapy.

The present invention is one kind of muscular atrophy treating medicine composition capable of dredging meridian, promoting blood circulation to disperse blood clots, eliminating external evil, invigorating spleen and kidney, raising body's immunity and reaching Yin-Yang balance. It is prepared with eight kinds of Chinese medicinal materials, including astragalus root, cassia, human placenta, schisandra, antler glue, etc. and through dispersing antler glue in boiling water, heating the medicine materials with water at 120 deg.c and 1.2-1.5 atm for 30-40 min to obtain medicine liquid, and packing. The present invention can regenerate necrotic muscle molecule to reach the aim of curing muscular atrophy.

The invention relates to application of polydatin which is an extract of polygonum cuspidatum. In-vitro researching experiments show that the polydatin has strong protecting effect for pathological injuries caused by rats multiple infarctional cerebral ischemic injuries, can significantly improve learning memory function of dementia model rats, so the polydatin can be used for preparing a product for resisting vascular dementia and a product, particularly a medicine for resisting senile dementia. The modes for using the polydatin include independent use, or combined use with other chemical substances. Dementia is a key disease impacting health of the elderly, particularly, frequency of disease development of the vascular dementia and the senile dementia is significantly increased to seriously threaten health and life of human beings. The invention provides a novel drug source for clinically treating the vascular dementia and the senile dementia, and has important value for developing and utilizing medicinal plant resource in China.

An oral applied Chinese medicine for treating both infectious pyreticosis and non-infectious fever diseases, and some infectious diseases is prepared from 8-14 Chinese-medicinal materials including sweet wormwood, bamboo shavings, pinellia tuber, tangerine peel, etc through steaming, reflux extracting in alcoholic aqueous solution and vacuum distilling for concentrating. Its advantage is high curative effect (93.3%).

This invention relates to a method for detecting Mycobacterium tuberculosis by utilizing gamete technique. This invention is aimed to solving the problems of low discovery rate and low curative rate of tuberculosis. The method comprises: utilizing gamete technique, performing bacteria culture or bioengineering method to obtain all kinds of targets of Mycobacterium tuberculosis, obtaining highly compatible specific gametes of the targets by gamete technique screening, and converting the gametes into report gametes for rapid and precise detection of corresponding targets. The method can further combine highly compatible gametes with pathogenetic factors to defunctionalize them, or develop new drugs by finding structural analogues of highly compatible gametes, thus can provides basis for diagnosis and clinical therapy of Mycobacterium tuberculosis.

The invention provides a gene chip used for detecting candida, relating to the biological field, and aiming to solve the problems that because mycotic infection is hard to diagnose, and the prior diagnosis method is relatively laggard and is always lagged behind clinical therapy, many patients can not get correct and timely diagnosis and lose therapy opportunity. The gene chip is characterized in that the chip comprises: (1) an oligonucleotide probe for detecting different types of candidas and a quality control oligonucleotide probe, and (2) a probe array formed by the oligonucleotide probes fixed on a carrier material through arm molecule. Moreover, the gene chip has the advantages of quick and accurate detection of candida infectious diseases as well as high sensitivity and specificity.

The invention discloses an oral administration pharmaceutical composition for treating chronic pelvic inflammatory disease, wherein the active constituents include the following raw material herbs (by weight portion): honeysuckle flower 20g, capsule of weeping forsythia 10g, spatholobus stem 10g, herba patriniae 10g, coix seed 10g, red peony root 2g, peach kernel 12g, corydalis tuber 9g, toosendan fruit 9g, frankincense 4. 5g, myrrh 4. 5g, rhizome of Sichuan lovage 6g, motherwort 10g, flavescent sophora root 10g. The medicament should be decocted in water for the oral dose.

The invention relates to a gel, in particular to an induced gel used for repairing skin wound surfaces or cervical mucosa, which not only can solve the therapy problems of skin wounds, cuts and ulcer wound surfaces but also can improve the micro-ecological environments of vaginae and repair the microdamage of the vaginae and meanwhile has good therapeutic effect on cervical erosion. The induced gel comprises Carbomer, triclosan and a recombination human epidermal growth factor, wherein the concentration of Carbomer is 3 to 5 percent, the concentration of triclosan is 0.1 to 0.6 percent, and the concentration of the recombination human epidermal growth factor is 0.00001 to 0.0005 percent. The induced gel can improve the micro-ecological environments of the vaginae and repair the microdamage of the vaginae, thereby being suitable for various vagina inflammations and cervicitis caused by vagina micro-ecological disorder and vagina damage and being suitable for the auxiliary therapy after the clinical therapy on vaginitis and cervicitis and the therapy on cervical erosion; the induced gel also can be used for treating the skin wounds, the cuts and the skin wound surfaces, thereby accelerating the repair and the regeneration of wound tissues, promoting healing and reducing scar formation.

The invention discloses an application of lncRNA (long no-coding RNA) which is LINC01983 in diagnosis and tretament of lung adenocarcinoma. Significant up-regulation of expression of the LINC01983 inlung adenocarcinoma is found for the first time, and large-sample QPCR experiments further prove that the LINC01983 can be applied to clinical diagnosis of the lung adenocarcinoma as a potential molecular target. The invention also discloses the LINC01983 related to proliferation, migration and invasion of lung adenocarcinoma cells, which indicates that the LINC01983 can be applied to clinical diagnosis of the lung adenocarcinoma as the potential molecular target.

The invention relates to a nasal cavity irradiating therapeutic head of a semiconductor laser therapeutic apparatus, which can reach effectiveness and safety requirements on laser clinical therapies. The nasal cavity irradiating therapeutic head comprises a laser, a heat-stabilized heat conducting device, a packing positioning device, a light guiding and transmitting device, a laser window cover, a housing, a nasal clip device and a power supply lead, wherein the heat-stabilized heat conducting device is designed according to heat balance temperature to control the operating temperature range of the laser, the light guiding and transmitting device is designed according to fiber optical light guide transmission so that the laser is far away from a laser irradiating window, which is beneficial to structural design; meanwhile, a fiber numerical aperture is used for ensuring the guide and the scattering output of scattered semiconductor laser. The housing is made from an insulating material and is an anti-static electromagnetic compatibility design, which prevents electrostatic interference from causing the laser power attenuation and the laser damage. The laser window cover is designed by adopting safe irradiation power density of a light outputting opening and laser scattering irradiation on light spots, the safety control of laser irradiation is provided, and thus the effectiveness of the clinical therapies and the safety of the laser irradiation can be ensured.

The invention relates to a model device for dynamic detection of root canal flushing effect and a detection method thereof. The invention is characterized in that the device is successively integrated as a whole by a transparent tooth model (1), a microscope (2), an electro-ocular (3), a notebook computer (4), a universal mechanics tester (5), an injector (6), a root canal flushing needle (7), a transparent tooth and injector fixing device (8) and a base station fixing device (9) through connectors. The detection method comprises the following steps: infusing a tracer with colors in the transparent tooth model (1) after connection of the model device for dynamic detection of root canal flushing effect is finished, while filling flushing liquid in the injector (6), driving the injector (6) by the universal mechanics tester (5) and flushing the tracer in the transparent tooth model (1) through the root canal flushing needle (7), and carrying out micro dynamic shooting with the microscope (2) and the electro-ocular (3) and storing in the notebook computer (4) to facilitate analysis of the root canal flushing dynamic effect and influence factors thereof. The method is to provide a scientific study method and clinical therapy basis for flushing the root canal.

The present invention concerns derivatives of heteroarylsulfonamides, notably as blockers of Kv potassium channels, and more particularly of channels Kv1.5, Kv4.3 or Kv11.1, their application in clinical therapy and their preparation methods. These compounds correspond to the following general formula (I): where R1 represents one or more substituents of the phenyl core X such as: hydrogen, halogen, trifluoromethyl, trifluoromethoxy, linear or branched C1-C4 alkyl, or linear or branched C1-C4 alkoxy, A represents oxygen or sulphur, B represents nitrogen when n=1 or 2 and D represents -C(=O)-, or B represents CH when n=0 and D represents -CH2O- or when n=1 and D represents -O-, R2 represents a hydrogen, a methyl, a fluorine or chlorine atom or a methoxy, HetAr represents a pyridyl or quinolyl group, possibly substituted by a group such as a linear or branched C1-C4 alkyl, a linear or branched C1-C4 alkoxy, a halogen, or a trifluoromethyl, and to their pharmaceutically acceptable salts.

The invention relates to a medicinal preparation for treating infantile repeated cold and improving infantile immunity, which is characterized by being prepared from purple bergenia, white sandalwood, tabasheer, lagotis brachystachy maxim, aconitum tanguticum stapf, alpine cochlearia officinalis and the like. The medicinal preparation can be prepared into oral preparations such as tablets, granules, oral liquid, syrup and the like and has the effects of clearing heat and dispelling wind and reducing phlegm and relieving cough, and the total effective rate of treating the infantile repeated cold and cough clinically is 94 percent. Adverse effects do not occur in the clinical observation process, so the medicinal preparation is an ideal medicament for treating the infantile cold.

The invention provides applications of bruceine D in preparing a Wnt/Notch signal channel inhibitor preventing/treating drug. The Wnt/Notch signal channel inhibitor preventing/treating drug is a drug composition which is prepared by taking bruceine D as an active ingredient, and is prepared from bruceine D and a pharmaceutic adjuvant, and can be prepared into oral preparations, injection preparations, or transdermal drugs. A human liver cancer tumor cell line model and a human normal liver cell line model are used for evaluating in vitro antitumor effect of bruceine D, a zebra fish model is used for evaluating inhibition effect of bruceine D on Wnt/Notch signal channel, and it is confirmed by experiment results that body axis dysplasia caused by inhibition of Wnt signal channel is observed when death of zebra fish is not caused by 100<mu>M of bruceine D. Influences of bruceine D on Wnt-Notch signal channel key proteins are disclosed by in vitro and vivo antitumor activity experiments of bruceine D for the first time, the important effect of Wnt-Notch signal channel on liver cancer, and the inner relationship of Wnt-Notch signal channel are confirmed, novel applications of bruceine D in preparing the drugs used for preventing/treating liver cancer are provided, the drugs used for preventing/treating liver cancer are provided for clinical therapy, and high application value is achieved.